USFDA Inspection Concludes at Jubilant Pharmova's Spokane Facility With 8 Observations

Jubilant Pharmova Limited announced that the United States Food and Drug Administration (USFDA) concluded an inspection at its subsidiary Jubilant HollisterStier LLC's contract manufacturing facility in Spokane, WA, U.S.A on June 17, 2026. The inspection resulted in eight observations, with none related to sterility assurance concerns, a critical metric for sterile injectable manufacturing operations.

Jubilant HollisterStier LLC intends to respond to the inspection observations within 15 business days. The company stated it is committed to addressing the observations comprehensively. The disclosure was made to the exchanges in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Inspection Details

The following table outlines the key details of the regulatory inspection:

Inspection Detail:	Information
Facility:	Jubilant HollisterStier LLC, Spokane, WA
Inspection Date:	June 17, 2026
Total Observations:	8
Sterility Assurance Concerns:	None
Response Timeline:	Within 15 business days

Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is under Jubilant Pharma Limited, Singapore. Jubilant Pharma Limited is a wholly owned subsidiary of Jubilant Pharmova Limited. The Spokane facility specialises in contract manufacturing for sterile injectables and ophthalmics.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.73%	+2.17%	-4.30%	-8.36%	-13.97%	+31.71%

Jubilant Pharmova has approved the re-appointment of its Managing Director and Joint Managing Director for a further term of three years. The Board of Directors approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director effective from June 1, 2026. The decision was taken during a board meeting held on May 22, 2026, and is subject to the approval of the shareholders.

The recommendations were based on the advice of the Nomination, Remuneration & Compensation Committee. Both directors were previously re-designated to their current roles in June 2023. The company disclosed the specific terms regarding the re-appointments in a regulatory filing submitted to BSE Limited and National Stock Exchange of India Limited.

Re-appointment Details

The table below outlines the key particulars for both directors as per the regulatory filing.

Particulars	Re-appointment of Mr. Priyavrat Bhartia	Re-appointment of Mr. Arjun Shanker Bhartia
Designation	Managing Director	Joint Managing Director
Date of Appointment	June 1, 2026	June 1, 2026
Term	3 years	3 years
Relationship	Son of Mr. Shyam Sunder Bhartia, Chairman	Son of Mr. Hari Shanker Bhartia, Co-Chairman

Director Profiles

Mr. Priyavrat Bhartia, 49 years old, possesses around 29 years of industry experience. He holds a Bachelor's Degree in Economics from Dartmouth College, USA, and a Master's in Business Administration from Stanford University, USA. He has served on the board since May 2017 and was re-designated as Managing Director in June 2023.

Mr. Arjun Shanker Bhartia, aged 39, is a graduate of Brown University, USA. He began his career as an Associate Consultant with Bain & Company and has been associated with Jubilant Pharmova Limited since May 2017. He was re-designated as Joint Managing Director with effect from June 2023. The board expressed confidence that the company will benefit significantly from their leadership and strategic contributions.